NCT00909818|UnknownDMC
Loading search results
Sponsor study identifier
Secondary identifiers
interventional
976
1 country
1
Study Start
May 14, 2009
Actual (reported)Primary Completion
May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to investigate the difference in late radiation morbidity between hypofractionated and standard fractionated breast irradiation given to women operated with breast conservation for early breast cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 14, 2009
Actual (reported)May 28, 2009
Actual (reported)May 29, 2009
Actual (reported)May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Grade 2 or 3 fibrosis 3 years after radiotherapy
3 years
Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival
10 years
50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
hypofractionated radiotherapy 40 Gy/15 fractions
standard fractionated radiotherapy 50 Gy/25 fractions
hypofractionated radiotherapy 40 Gy/15 fractions
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The Danish Breast Cancer Cooperative Group
Copenhagen, DK-2100 Ø, Denmark
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, Overgaard J; Danish Breast Cancer Group Radiation Therapy Committee. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol. 2020 Nov 1;38(31):3615-3625. doi: 10.1200/JCO.20.01363. Epub 2020 Sep 10.
Lars Stenbygaard, MD
Aalborg University Hospital
Birgitte Offersen, MD, Ph.D
Aarhus University Hospital
Erik Jakobsen, MD
Vejle Hospital
Mette H Nielsen, MD, phd
Odense University Hospital
First Submitted
May 28, 2009
First Posted
May 29, 2009
Study Start
May 14, 2009
Actual (reported)Primary Completion
May 2024
Estimated (date passed)Hypofractionated Versus Conventional Fractionation Radiotherapy
Contact the study team to confirm eligibility.
Birgitte Offersen, MD, phd
Aarhus University Hospital
Mechthild Krause, M.D., Prof
University Clinic Carl Gustav Carus Dresden
Andreas Schreiber, M.D., Ph.D.
Praxis für Strahlentherapie am Klinikum Dresden-Friedrichstadt
Ingvil Mjaaland, M.D.
Helse Stavanger HF, Sorlandet Sykehus HF
Unn-Miriam Kasti, M.D.
Kristiansand Sykehus
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 24, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: